Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Friday . The company traded as high as C$12.15 and last traded at C$12.14, with a volume of 809 shares trading hands. The stock had previously closed at C$11.89.
Fennec Pharmaceuticals Trading Up 2.3%
The company has a debt-to-equity ratio of -620.83, a quick ratio of 10.17 and a current ratio of 7.80. The company has a market capitalization of C$234.50 million, a price-to-earnings ratio of -205.99 and a beta of 0.25. The business's 50-day simple moving average is C$10.37 and its 200-day simple moving average is C$9.33.
Insider Activity
In related news, Director Jeffrey Hackman purchased 15,000 shares of the stock in a transaction dated Monday, May 19th. The stock was bought at an average cost of C$9.77 per share, with a total value of C$146,580.00. Also, Senior Officer Robert Christopher Andrade bought 8,220 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were acquired at an average cost of C$6.99 per share, with a total value of C$57,433.14. Insiders sold a total of 38,076 shares of company stock valued at $391,650 in the last ninety days. 16.20% of the stock is owned by insiders.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
Featured Articles
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
